Abstract
Rheumatoid arthritis (RA) associates with excess cardiovascular morbidity and mortality, resulting in significantly shortened lifespan. Traditional risk factors (e.g. dyslipidaemia and hypertension) and novel risk factors (e.g. systemic inflammation) contribute to the development of cardiovascular disease (CVD) in RA. In the general population, dyslipidaemia has been found to be central to the development of CVD, playing an important role in all stages of atherosclerotic plaque formation. In RA, lipid metabolism may be altered by systemic inflammation, environmental lifestyle factors, drug therapy and several genetic factors. This may result in changes in overall lipid levels, as well as modifications of lipid/lipoprotein structure and function. In this review, we discuss lipid abnormalities specifically in the context of RA and highlight the potential impact of inflammation, genetic factors, lifestyle, and anti-rheumatic drugs on lipid metabolism.
Keywords: Rheumatoid arthritis, dyslipidaemia, inflammation, drugs, genetics, lifestyle, environment
Current Vascular Pharmacology
Title: Dyslipidaemia in Rheumatoid Arthritis: The Role of Inflammation, Drugs, Lifestyle and Genetic Factors
Volume: 8 Issue: 3
Author(s): Tracey E. Toms, Deborah P. Symmons and George D. Kitas
Affiliation:
Keywords: Rheumatoid arthritis, dyslipidaemia, inflammation, drugs, genetics, lifestyle, environment
Abstract: Rheumatoid arthritis (RA) associates with excess cardiovascular morbidity and mortality, resulting in significantly shortened lifespan. Traditional risk factors (e.g. dyslipidaemia and hypertension) and novel risk factors (e.g. systemic inflammation) contribute to the development of cardiovascular disease (CVD) in RA. In the general population, dyslipidaemia has been found to be central to the development of CVD, playing an important role in all stages of atherosclerotic plaque formation. In RA, lipid metabolism may be altered by systemic inflammation, environmental lifestyle factors, drug therapy and several genetic factors. This may result in changes in overall lipid levels, as well as modifications of lipid/lipoprotein structure and function. In this review, we discuss lipid abnormalities specifically in the context of RA and highlight the potential impact of inflammation, genetic factors, lifestyle, and anti-rheumatic drugs on lipid metabolism.
Export Options
About this article
Cite this article as:
E. Toms Tracey, P. Symmons Deborah and D. Kitas George, Dyslipidaemia in Rheumatoid Arthritis: The Role of Inflammation, Drugs, Lifestyle and Genetic Factors, Current Vascular Pharmacology 2010; 8 (3) . https://dx.doi.org/10.2174/157016110791112269
DOI https://dx.doi.org/10.2174/157016110791112269 |
Print ISSN 1570-1611 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6212 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Targeting the MCP-1/CCR2 System in Diabetic Kidney Disease
Current Vascular Pharmacology Polyphenols from Red Wine Modulate Immune Responsiveness: Biological and Clinical Significance
Current Pharmaceutical Design Editorial [Hot Topic: Modifying Coronary Risk Factors: C-Reactive Protein,Haemostatic Factors and Cardiovascular Risk (Executive Editor: Aurelio Leone)]
Current Pharmaceutical Design Cardiac Metabolism in Myocardial Ischemia
Current Pharmaceutical Design Editorial [Hot Topic: Drugs Targeting Atherosclerosis: Current and Emerging Approaches (Executive Editors: Vangelis G. Manolopoulos and Anna Tavridou)]
Current Pharmaceutical Design Peroxisome Proliferator-Activated Receptor (PPAR) in Metabolic Syndrome and Type 2 Diabetes Mellitus
Current Diabetes Reviews Is Peri-Operative Isolated Systolic Hypertension (ISH) a Cardiac Risk Factor?
Current Cardiology Reviews Non-pharmacological Strategies Against Systemic Inflammation: Molecular Basis and Clinical Evidence
Current Pharmaceutical Design To Bleed or Not to Bleed: That is the Question. The Side Effects of Apixaban
Current Drug Targets Relation of Neck Circumference with Total Body Fat and BMI
Current Nutrition & Food Science A Yeast Extract High in Bioactive Peptides has a Blood-Pressure Lowering Effect in Hypertensive Model
Current Medicinal Chemistry Graphical Abstracts
Protein & Peptide Letters Hepatocellular Carcinoma in Alcoholic Liver Disease: Current Management and Recent Advances
Reviews on Recent Clinical Trials Current Update in the Management of Diabetic Nephropathy
Current Diabetes Reviews Biomarkers as a Guide of Medical Treatment in Cardiovascular Diseases
Current Medicinal Chemistry Renal Venous Thrombosis in Neonates
Current Pediatric Reviews Anti-hyperglycemic Properties of a Purified Proteinaceous Protease Inhibitor from Macrotyloma Uniflorum Seeds
Current Topics in Medicinal Chemistry Antioxidant Phytochemicals in Pulses and their Relation to Human Health: A Review
Current Pharmaceutical Design Halogen Dance Reaction and its Application in Organic Synthesis
Current Organic Chemistry The Cardiovascular Effects of Metformin: Further Reasons to Consider An Old Drug as a Cornerstone in the Therapy of Type 2 Diabetes Mellitus
Current Vascular Pharmacology